Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM

Journal of Human Hypertension

Volumn 21, Issue 12, 2007, Pages 917-924

  Puig, J G ^a   Calvo, C ^b   Luurila, O ^c   Luurila, H ^c   Sulosaari, S ^d   Strandberg, A ^d   Ghezzi, C ^e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Kaisaniemen Lääkariasema Oy   (Finland)

^d Keravan LäKärikeskus   (Finland)

^e Recordati SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ENALAPRIL; LERCANIDIPINE; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VERTIGO;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; DIASTOLE; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLACEBOS; SYSTOLE; TIME FACTORS;

EID: 36448942169     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002248     Document Type: Article

References (18)

1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
2. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guide-lines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
3. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363: 2049-2051.
4. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al., The Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170-2179.
5. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure Teasurements. J Hypertens 1998; 16: 1831-1838.
6. Bang LM, Chapman TM, Goa KL. Lercanidipine. A review of its efficacy in the management of hypertension. Drug 2003; 63: 2449-2472.
7. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005; 1: 173-182.
8. Todd PA, Goa LG. Enalapril: A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 43: 346-381.
9. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.
10. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-848.
11. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16: 1685-1691.
12. Mancia G, Parati G. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment with calcium antagonists. In: Epstein M (ed). Calcium Antaognists in Clinical Medicine. Hanley and Belfus: Philadelphia, 2002, pp 117-137.
13. Staessen JA, Thijs L. Fagard R, O'Brien ET, Clement D, de Leeuw PW et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe Trial Investigators. JAMA 1999; 282: 539-46.
14. Mancia G, Zanchetti A, Agabiti Rosei E, Benemio G, De Cesaris R, Fogari R et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. The SAMPLE study group. Circulation 1997; 95: 1464-1470.
15. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, on behalf of the COHORT Study Group. Tolerability of long-term treatment with lercanidipine vs amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-940.
16. Lund-Johansen P, Stranden E, Helberg S, Wessel-Aas T, Risberg K, Ronnevik PK et al. Quantification of leg oedema in post menopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003; 21: 1003-1010.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
18. Julius S, Kjeldsen E, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.